CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(02): 139-143
DOI: 10.1055/s-0041-1732491
Original Article

Immunoexpression of CD34, CD117, and p53 in Hypocellular Bone Marrow Disorders

Pooja Sharma
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
Anshu Palta
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
Anita Tahlan
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
Manveen Kaur
1   Department of Pathology, Government Medical College and Hospital, Chandigarh, India
Ram Singh
2   Department of Medicine, Government Medical College and Hospital, Chandigarh, India
› Author Affiliations


Objectives Hypocellular bone marrow (BM) disorders comprise heterogeneous entities associated with peripheral cytopenias and decreased production of hematopoietic cells in BM. This study was undertaken to analyze immunohistochemical expression of CD34, CD117, and p53 in morphologically diagnosed patients of hypocellular BM (aplastic anemia [AA], hypocellular myelodysplastic syndrome [h-MDS], and hypocellular acute myeloid leukemia [h-AML]).

Materials and Methods BM specimens were obtained from patients presenting with pancytopenia/bicytopenia. On 30 patients diagnosed as hypocellular BM, immunohistochemistry (IHC) for CD34, CD117, and p53 was performed.

Results BM cellularity was < 30% in all (100%) patients. Blast count was increased in h-MDS and h-AML. Features of dysplasia were noted in six (20%) patients. Out of these, three patients were diagnosed as h-MDS having bilineage/trilineage dysplasia, and the other three patients were of AA (11.5% patients) displaying only dyserythropoiesis. On IHC, percentage of BM CD34+ cells was increased in h-MDS+ h-AML (3.87 ± 0.86) as compared with AA (0.19 ± 0.15) and controls (0.81 ± 0.21), p = 0.01. Percentage of BM p53+ cells was also increased in h-MDS+ h-AML (2.9 ± 2.07) as compared with AA and controls, which did not show any p53+ cells, p = 0.0. No statistically significant difference was observed in the expression of CD117 in h-MDS+ h-AML (4.95 ± 3.40) compared with AA (4.49 ± 1.07), p = 0.99.

Conclusion The study demonstrates the usefulness of CD34 and p53 immunoexpression as an important ancillary method in distinguishing various hypocellular BM disorders, especially h-MDS and AA. However, the role of CD117 remains unclear and needs to be evaluated further by larger studies.

Publication History

Article published online:
24 August 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica 2009; 94 (02) 264-268
  • 2 Rovó A, Tichelli A, Dufour C. SAA-WP EBMT. Diagnos is of acquired aplastic anemia. Bone Marrow Transplant 2013; 48 (02) 162-167
  • 3 DeZern AE, Sekeres MA. The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist 2014; 19 (07) 735-745
  • 4 Marsh JW, Young NS. Acquired aplastic anaemia. In: Hoffbrand AV, Catovsky A, Tuddenham EGD, Green AR. eds. Hoffbrand. 6th edition. West Sussex, UK: Wiley Blackwell; 2011: 206-224
  • 5 Melinkeri SR. Epidemiology, pathogenesis and diagnosis of aplastic anaemia. J Assoc Physicians India 2015; 63 (3, Suppl) 8-12
  • 6 Issaragrisil S, Kaufman DW, Anderson T. et al. The epidemiology of aplastic anemia in Thailand. Blood 2006; 107 (04) 1299-1307
  • 7 Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica 2008; 93 (04) 489-492
  • 8 Marsh JC, Ball SE, Cavenagh J. et al. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147 (01) 43-70
  • 9 Montané E, Ibáñez L, Vidal X. et al. Catalan Group for Study of Agranulocytosis and Aplastic Anemia. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008; 93 (04) 518-523
  • 10 Raghupathy R, Derman O. Response of paroxysmal nocturnal hemoglobinuria clone with aplastic anemia to rituximab. Case Rep Hematol 2012; 2012: 106182
  • 11 Sekeres MA. Myelodysplastic syndromes: it is all in the genes. J Clin Oncol 2012; 30 (08) 774-776
  • 12 Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109 (08) 1536-1542
  • 13 Manero GG. The myelodysplastic syndromes. In: Greer JP, Forester J, Rodgers GM, Paraskevas F, Glader B, Arber DA. eds. Wintrobe’s Clinical Haematology. 13th edition. Philadelphia: Lippincott Williams and Wilkins; 2014: 1673-1687
  • 14 Cha CH, Park CJ, Chi HS. et al. CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome from aplastic anaemia and a CD34 immunochemical stain provides useful survival information for hypoplastic myelodysplastic syndrome. Ann Lab Med 2014; 34: 42632
  • 15 Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 2006; 20 (03) 458-462
  • 16 Huh HJ, Chae SL, Lee M. et al. CD34, RAB20, PU.1and GFI1 mRNA expression in MDS. Int J Lab Hematol 2009; 31: 344-351
  • 17 Briggs C, Bain BJ. Basic haematological techniques. In: Bain BJ, Bates I, Laffar MA, Lewis SM. eds. Dacie and Lewis Practical Haematology. 11th edition. London: Elsevier; 2012: 23-56
  • 18 Hemoglobin concentration for diagnosis of anemia and assessment of severity. Geneva, World Health Organization, 2011. Available at: Accessed June 15, 2021
  • 19 Sekhon SS, Roy V. Thrombocytopenia in adults: a practical approach to evaluation and management. South Med J 2006; 99 (05) 491-498 , quiz 499–500, 533
  • 20 Hasserjian RP, Orazi A, Brunning RD. et al. Myelodysplastic syndromes overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th edition. Lyon: France; 2017: 98-117
  • 21 Jackson P, Blythe D. Immunohistochemical techniques. In: Bancroft J, Layton C, Suvarna SK. eds. Theory and Practice of Histological Techniques. 7th edition. Philadelphia: Elsevier; 2012: 381-426
  • 22 Brodsky RA. Acquired aplastic anaemia. In: Greer JP, Forester J, Rodgers GM, Paraskevas F, Glader B, Arber DA. eds. Wintrobe’s Clinical Haematology. 12th edition. Philadelphia: Lippincott Williams and Wilkins; 2009: 1185-1195
  • 23 Young NS, Colado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108 (08) 2509-2519
  • 24 Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol 2011; 38 (05) 667-672
  • 25 Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program 2011; 2011: 84-89
  • 26 Mahapatra M, Singh PK, Agarwal M. et al. Epidemiology, clinico-haematological profile and management of aplastic anaemia: AIIMS experience. J Assoc Physicians India 2015; 63 (3, Suppl) 30-35
  • 27 Shao Z, Chen G, Zhang H. [Expression of c-kit receptor on the hemopoietic stem/precursor cells of aplastic anemia patients]. Zhonghua Xue Ye Xue Za Zhi 1999; 20 (10) 532-534
  • 28 Tavil B, Cetin M, Tuncer M. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome. Leuk Res 2006; 30 (02) 222-224